'Extraneous data collected in clinical trials cost drug developers $4-bn to $6-bn annually'

摘要

One out of every five procedures performed during later stage clinical trials collects extraneous data and costs drug developers more than $l-mn per trial, a newly completed study by the US-based Tufts Center for the Study of Drug Development has found. According to Tufts CSDD, 18 per cent of a typical clinical trial budget, or $ Limn, is spent on direct costs to administer procedures for supplementary secondary, tertiary, and exploratory endpoints.